Fmoc-alpha-Me-L-Leu-OH

Fmoc-alpha-Me-L-Leu-OH is an Fmoc-protected, stereodefined amino acid derivative bearing an α-methylated leucine side-chain framework, where the N-terminus is masked as an Fmoc carbamate and the C-terminus is present as a free carboxylic acid. The molecule contains a single chiral center at the α-position relative to the carboxylate and the Fmoc-bearing nitrogen, and the α-methyl substitution increases steric differentiation around the peptide coupling site. The leucine-derived isobutyl side chain provides hydrophobic character, while the free carboxylic acid supports standard peptide coupling chemistry and downstream conversion to activated esters or amide-forming intermediates. The Fmoc group is compatible with base-labile deprotection strategies, enabling controlled exposure of the amino functionality during stepwise peptide assembly and supporting chiral building block use in synthetic and biochemical research workflows.

1. Peptide Synthesis

Fmoc-alpha-Me-L-Leu-OH is used in solid-phase and solution-phase peptide synthesis where an α-methylated, Fmoc-protected amino acid building block is required to tune backbone sterics and conformational preferences. The Fmoc carbamate protects the amino group during coupling cycles, while the free carboxylic acid can be converted to common coupling partners to form amide bonds with protected amino acids. The α-methyl stereochemistry and leucine side-chain hydrophobicity can be leveraged to construct peptide sequences with altered proteolytic stability and modified secondary-structure propensities, supporting peptide analog construction for research-grade scaffold generation. Stepwise Fmoc deprotection and re-coupling compatibility makes the compound suitable for iterative synthesis of α-methylated peptide fragments and longer peptidomimetic chains.

2. Peptidomimetics And SAR

Fmoc-alpha-Me-L-Leu-OH serves as a chiral intermediate for peptidomimetic construction in structure-activity relationship studies where α-methylation is used to modulate backbone rigidity and side-chain presentation. The α-methyl substituent creates a stereochemically defined steric environment adjacent to the amide linkage, while the leucine isobutyl side chain contributes hydrophobic contacts that can be reflected in binding-site interactions. Fmoc protection enables incorporation into defined sequences during SAR library synthesis, and the free carboxylic acid supports generation of peptide-coupling derivatives for fragment assembly. The resulting α-methylated residues can be used to build analog series for mapping how stereochemistry and backbone substitution influence molecular recognition in biochemical screening contexts.

3. Chemical Biology Labeling

Fmoc-alpha-Me-L-Leu-OH is applicable to chemical biology workflows that require incorporation of an amino acid residue into peptides or peptide-like probes bearing defined stereochemistry. The Fmoc-protected amine supports controlled deprotection to generate a primary amine at the desired synthetic stage, enabling subsequent conjugation chemistry after peptide assembly. The leucine-derived hydrophobic side chain can help maintain solubility and membrane-relevant behavior of labeling probes, while the α-methyl center can improve structural persistence of the probe scaffold. Downstream functionalization can be performed on the assembled peptide framework, with the compound acting as a stereodefined building block for generating labeled biomolecule mimetics and analytical reagents.

4. Protected Amino Acid Chemistry

Fmoc-alpha-Me-L-Leu-OH is suitable for protected amino acid synthesis planning because it combines an Fmoc-protected nitrogen with a free carboxylic acid handle for controlled derivatization. The Fmoc group provides an orthogonal protection strategy compatible with standard peptide coupling cycles, allowing selective exposure of the amino functionality without disturbing the α-methyl stereocenter. The α-methylated leucine motif can be employed as a chiral intermediate for preparing additional protected derivatives, including activated carboxylate forms or orthogonally protected side-chain variants when targeted peptide architectures require further functional-group tuning. The compound thereby functions as a practical chiral building block for manufacturing route design in fine chemical synthesis where stepwise protection and deprotection logic is central.

5. Pharmaceutical Intermediate Preparation

Fmoc-alpha-Me-L-Leu-OH is used as an amino acid intermediate in the preparation of peptide-based drug candidates and related process intermediates where α-methylated residues are incorporated to influence stability and developability profiles. The free carboxylic acid enables conversion into activated species for amide bond formation under common peptide-manufacturing conditions, while the Fmoc carbamate supports controlled N-protection during multistep assembly. The stereodefined α-methyl center and leucine hydrophobic side chain can be carried through to final peptide intermediates with defined backbone substitution patterns, supporting reproducible synthesis of analog series. The compound's protection pattern aligns with scalable peptide construction logic, making it relevant to pharmaceutical intermediate preparation and specialty chemical production of α-methylated peptide fragments.

1. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

2. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function

3. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

4. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics

5. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment